Muscle Pharm Corp (fka MSLPQ)

[learning curve]

ID; for the most part I'm following you....except Gary clearly outlined that it is 1.628m that will be trailing into Q2. That's it.

I also thought; am almost sure the derivative expense is solely associated with the convertible shares that to date have yet to be converted. So...the derivative expense will continue to rise until converted AS THE PPS CONTINUES TO RISE...so this expense can NOT be forecasted and is virtually negligible as it is NOT attached to any dilution rights etc....

This is my interpetation atleast. Yours?